Pre-scan for PSMA radiation therapy in metastatic prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial tests whether a special PET scan can predict how well a targeted radiation therapy (177Lu-PSMA-617) works for men with advanced prostate cancer that has stopped responding to hormone therapy. It aims to personalize treatment by checking the radiation dose before therapy starts.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are over 18 years old and have metastatic prostate cancer that has spread to other parts of the body.
- Your cancer has stopped responding to hormone therapy, and you have already tried chemotherapy with a taxane drug and at least one next-generation hormone therapy.
- You are able to have three different PET scans as part of your regular care to check if you are eligible for treatment.
- You are generally well enough to manage daily activities (ECOG score 0-2) and your doctor expects you to live at least 6 more months.
- You can lie still on your back for about 1 hour and 20 minutes for a special scan.
- You do not have a pacemaker, defibrillator, or any condition that makes the scans or treatment unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses two types of PET scans (PSMA and FDG) to see how well a radioactive therapy called 177Lu-PSMA might work for men with advanced prostate cancer that has stopped responding to hormone therapy and chemotherapy.
This trial will test if a special PET scan (18F-DCFPyL) can help doctors plan your treatment with a radioactive medicine called 177Lu-vipivotide tetraxetan. You are eligible if you already qualify for that standard therapy and have had a prior PSMA PET scan showing at least one active cancer site.
This trial is testing if a higher first dose of Lu-177-PSMA-617, a targeted radiation therapy, can improve outcomes for men with metastatic castration-resistant prostate cancer that shows up on a PSMA PET scan. The goal is to see if it is safe and effective.
This trial tests a higher dose of a radioactive drug (177Lu-PSMA-617) for men whose prostate cancer has spread and does not produce much of a protein called PSMA on scans. The goal is to see if a stronger dose can work better than the standard dose.
This trial studies whether a PSMA-targeted treatment using 177Lu can help men with prostate cancer that has spread and is growing despite hormone treatment. It may help if your scan shows high PSMA in the tumor and your blood counts and organ function are adequate.
This study is testing whether a special scan (dosimetry) can help predict how well PSMA radioligand therapy works for men with advanced prostate cancer that has spread. The therapy uses a radioactive drug to target and kill cancer cells that have a protein called PSMA.
Hear when a new Patients With Metastatic Castration-resistant Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.